Review
Nature Reviews Cancer 2, 489-501 (July 2002) | doi:10.1038/nrc839
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Igor Vivanco1 & Charles L. Sawyers1 About the authors
Abstract
One signal that is overactivated in a wide range of tumour types is the production of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K). This lipid and the protein kinase that is activated by it — AKT — trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumour progression. Small-molecule therapeutics that block PI3K signalling might deal a severe blow to cancer cells by blocking many aspects of the tumour-cell phenotype.
- View At a Glance
Author affiliations
- Departments of Medicine, Molecular and Medical Pharmacology, Urology and Molecular Biology Institute, UCLA School of Medicine, 11-935 Factor Building, 10833 LeConte Avenue, Los Angeles, California 90095, USA.
Correspondence to: Charles L. Sawyers1 Email: csawyers@mednet.ucla.edu
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE NEWS AND VIEWS RESEARCH |
